These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 7388786)

  • 1. Active transport of methotrexate from cerebrospinal fluid in humans.
    Bode U; Magrath IT; Bleyer WA; Poplack DG; Glaubiger DL
    Cancer Res; 1980 Jul; 40(7):2184-7. PubMed ID: 7388786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probenecid inhibition of methotrexate-cerebrospinal fluid pharmacokinetics in dogs.
    Ramu A; Fusner JE; Blaschke T; Glaubiger DL
    Cancer Treat Rep; 1978 Oct; 62(10):1465-70. PubMed ID: 581360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection.
    Bleyer WA; Dedrick RL
    Cancer Treat Rep; 1977 Jul; 61(4):703-8. PubMed ID: 577895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?
    Niemann A; Mühlisch J; Frühwald MC; Gerss J; Hempel G; Boos J
    Ther Drug Monit; 2010 Aug; 32(4):467-75. PubMed ID: 20571463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of probenecid on ventricular cerebrospinal fluid methotrexate pharmacokinetics after intralumbar administration in nonhuman primates.
    Salzer W; Widemann B; McCully C; Adamson PC; Balis FM
    Cancer Chemother Pharmacol; 2001 Sep; 48(3):235-40. PubMed ID: 11592346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A primate model for study of methotrexate pharmacokinetics in the central nervous system.
    Poplack DG; Bleyer WA; Wood JH; Kostolich M; Savitch JL; Ommaya AK
    Cancer Res; 1977 Jul; 37(7 Pt 1):1982-5. PubMed ID: 405092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution and degradation of [3H]methotrexate after intravenous and cerebral intraventricular injection in primates.
    Kimelberg HK; Biddlecome SM; Bourke RS
    Cancer Res; 1977 Jan; 37(1):157-65. PubMed ID: 401470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration.
    Balis FM; Blaney SM; McCully CL; Bacher JD; Murphy RF; Poplack DG
    Cancer Chemother Pharmacol; 2000; 45(3):259-64. PubMed ID: 10663645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cerebrospinal fluid methotrexate level in children treated with medium-high and high doses of the drug].
    Wysocki M; Balcar-Boroń A; Krzyzanowski M; Szadujkis-Szadurski L; Ozyński T; Nowaczyk-Michalak A
    Acta Haematol Pol; 1992; 23(3):185-90. PubMed ID: 1492543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of renal tubular transport of methotrexate by probenecid.
    Bourke RS; Chheda G; Bremer A; Watanabe O; Tower DB
    Cancer Res; 1975 Jan; 35(1):110-6. PubMed ID: 1109785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate.
    Breithaupt H; Küenzlen E
    Cancer Treat Rep; 1982 Sep; 66(9):1733-41. PubMed ID: 6956440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effects of citrovorum factor and carboxypeptidase G1 on cerebrospinal fluid-methotrexate pharmacokinetics.
    Abelson HT; Ensminger W; Rosowsky A; Uren J
    Cancer Treat Rep; 1978 Oct; 62(10):1549-52. PubMed ID: 309355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration.
    Blasberg RG; Patlak CS; Shapiro WR
    Cancer Treat Rep; 1977 Jul; 61(4):633-41. PubMed ID: 406996
    [No Abstract]   [Full Text] [Related]  

  • 14. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections.
    Shapiro WR; Young DF; Mehta BM
    N Engl J Med; 1975 Jul; 293(4):161-6. PubMed ID: 806016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetics of intrathecal chemotherapy and clinical problems].
    Fujimoto T
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1536-42. PubMed ID: 6433796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebral subarachnoid sampling of cerebrospinal fluid in the rhesus monkey.
    Bacher JD; Balis FM; McCully CL; Godwin KS
    Lab Anim Sci; 1994 Apr; 44(2):148-52. PubMed ID: 8028278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of probenecid on cerebrospinal fluid methotrexate kinetics.
    Howell SB; Olshen RA; Rice JA
    Clin Pharmacol Ther; 1979 Nov; 26(5):641-6. PubMed ID: 498706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of methotrexate transport from cerebrospinal fluid by probenecid.
    Spector R
    Cancer Treat Rep; 1976 Jul; 60(7):913-6. PubMed ID: 1009521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of probenecid on brain-cerebrospinal fluid-blood distribution kinetics of E-Delta 2-valproic acid in rabbits.
    Scism JL; Powers KM; Artru AA; Chambers AC; Lewis L; Adkison KK; Kalhorn TF; Shen DD
    Drug Metab Dispos; 1997 Dec; 25(12):1337-46. PubMed ID: 9394022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion.
    Evans WE; Hutson PR; Stewart CF; Cairnes DA; Bowman WP; Rivera G; Crom WR
    Clin Pharmacol Ther; 1983 Mar; 33(3):301-7. PubMed ID: 6600662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.